RT Journal Article
T1 The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome.
A1 Pérez de Llano, Luis
A1 Dacal Rivas, David
A1 Marina Malanda, Nuria
A1 Plaza Moral, Vicente
A1 Gullón Blanco, José Antonio
A1 Muñoz-Esquerre, Mariana
A1 García-Moguel, Ismael
A1 Díaz Campos, Rocío M
A1 Martínez-Moragón, Eva
A1 Harbenau Mena, Alicia
A1 Cosío, Borja G
A1 Padilla Galo, Alicia
A1 Cisneros Serrano, Carolina
K1 COPD
K1 asthma
K1 asthma–COPD overlap
AB Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months. Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with ≥1 exacerbation and ≥1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of "controlled" patients (with no exacerbations, no need for corticosteroids and ACT ≥ 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients.
SN 1178-6965
YR 2022
FD 2022-03-18
LK http://hdl.handle.net/10668/20466
UL http://hdl.handle.net/10668/20466
LA en
DS RISalud
RD Apr 10, 2025